Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

Publisher DOI
PubMed ID
20713848
Description
Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied.
Date of Publication
2010
Publication Type
Article
Language(s)
en
Contributor(s)
Eich, Hans Theodor
Diehl, Volker
Görgen, Helen
Markova, Jana
Debus, Jürgen
Ho, Anthony
Dörken, Bernd
Rank, Andreas
Grosu, Anca-Ligia
Wiegel, Thomas
Karstens, Johann Hinrich
Greil, Richard
Willich, Normann
Schmidberger, Heinz
Döhner, Hartmut
Borchmann, Peter
Müller-Hermelink, Hans-Konrad
Müller, Rolf-Peter
Engert, Andreas
Additional Credits
Series
Journal of clinical oncology
Publisher
American Society of Clinical Oncology
ISSN
0732-183X
Access(Rights)
metadata.only
Show full item